13.07.2018
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition products nu3 GmbH, Berlin.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Takeover/Capital
Increase
SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition
products nu3 GmbH, Berlin.
13.07.2018 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR PUBLICATION IN THE
UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR IN ANY JURISDICTION
IN WHICH OFFERING OR SELLING THE SECURITIES WOULD BE PROHIBITED BY
APPLICABLE LAW.
SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition
products
nu3 GmbH, Berlin.
* Acquisition of a leading online company for superfoods and functional
nutrition with a European presence.
* Complementary products and target groups enhance the positioning and
economic value of SHOP APOTHEKE EUROPE.
* Financing by issuance of new shares and a cash payment.
* Founders and JAHR-Group, Hamburg, become shareholders of SHOP APOTHEKE
EUROPE.
Venlo, the Netherlands, July 13, 2018. SHOP APOTHEKE EUROPE N.V. (the
"Company" or "SHOP APOTHEKE EUROPE") has signed a contract yesterday to
purchase all shares in nu3 GmbH, Berlin. SHOP APOTHEKE EUROPE Group acquired
nu3 by means of an issue of a total of 54,470 new shares of SHOP APOTHEKE
EUROPE in bearer form and an additional cash payment. The issuance of new
shares and the exclusion of the pre-emptive rights in relation thereto has
been approved by the supervisory board of the Company. In financial year
2017, nu3 GmbH achieved revenues of approximately EUR 30 million, of which
approximately EUR 20 million were generated in European markets outside
Germany. In addition to revenue increases for both companies in their core
market Germany as well as in other European target markets such as France,
SHOP APOTHEKE EUROPE expects faster and profitable growth in the coming
years by leveraging synergies.
With the acquisition of nu3 GmbH, SHOP APOTHEKE EUROPE further expands its
positioning and value creation in its European markets: In addition to
expanding the product range with complementary products, cross-selling
potentials will emerge by addressing additional customers. nu3 GmbH is
already active in major European markets and operates in the fast-growing
market segment of functional nutrition products. The high-quality product
range of nu3 which comprises natural food and health products, low carb
products and sports nutrition has strong and well-known brands.
Michael Köhler, CEO of SHOP APOTHEKE EUROPE, explains: "nu3's business
ideally complements our offering for the target group of health-conscious
customers and provides us with the opportunity to grow even faster and with
sustainable profitability, both in Germany and especially in our young
markets such as France".
Dr. Robert Sünderhauf, founder and CEO of nu3 GmbH, adds: "We are looking
forward to further expanding the attractive growth potential of the online
market for superfoods and functional nutrition together with SHOP APOTHEKE
EUROPE and to further strengthen the nu3 brand. The product ranges and
customer groups as well as the European market presence perfectly complement
each other".
The founders of nu3, who are significantly driving further expansion with
SHOP APOTHEKE EUROPE, will become shareholders of SHOP APOTHEKE EUROPE
together with the JAHR-Group, Hamburg.
Subject to the successful completion of the transaction, the management
board of the Company intends to further specify the Group's growth forecast
for the financial year 2018 with the publication of the half-year financial
report on August 14, 2018 in accordance with the integration progress.
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in
Continental Europe. With the acquisition of Europa Apotheek Venlo in
November 2017, SHOP APOTHEKE EUROPE significantly extended its European
market leadership with an expanded product range for the whole family in the
areas of OTC, beauty and care products as well as prescription drugs.
SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria,
France, Belgium, Italy, Spain and the Netherlands. In Germany, the
TÜV-certified shop-apotheke.com is the market leading. SHOP APOTHEKE EUROPE
delivers a broad range of more than 100,000 original products to over 2.8
million active customers quickly and at attractive prices. In addition, SHOP
APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical
services.
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the
Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.
MEDIA CONTACTS.
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: [email protected]
Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: [email protected]
DISCLAIMER.
This announcement does not contain or constitute or form part of, and should
not be construed as, an offer or invitation to sell, or the solicitation of
an offer to buy or subscribe for, any securities of SHOP APOTHEKE EUROPE.
The distribution of this announcement and the offer and sale of the
securities referred to herein may be restricted by law in certain
jurisdictions and persons reading this announcement should inform themselves
about and observe any such restriction. Any failure to comply with these
restrictions may constitute a violation of the securities laws of any such
jurisdiction.
This announcement is not for publication or distribution, directly or
indirectly, in or into the United States, Australia, Canada or Japan or in
any jurisdiction in which offers or sales of the securities referred to
herein would be prohibited by applicable laws.
The securities referred to herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or
the laws of any state within the United States or under the applicable
securities laws of Australia, Canada or Japan, and may not be offered or
sold in the United States, unless registered under the Securities Act or
offered and sold in a transaction exempt from, or not subject to, the
registration requirements of the Securities Act. The securities referred to
herein are being offered and sold only outside the United States in
"offshore transactions" as defined in and in accordance with Regulation S
under the Securities Act. Subject to certain exceptions, the securities
referred to herein may not be offered or sold in Australia, Canada or Japan
or to, or for the account or benefit of, any national, resident or citizen
of Australia, Canada or Japan. There will be no public offer of the
securities referred to herein in the United States, Australia, Canada or
Japan.
The offer referred to herein when made in member states of the European
Economic Area (the "EEA") which have implemented the Prospectus Directive
(each, a "Relevant Member State"), is only addressed to and directed at
persons who are "qualified investors" (as defined in the Prospectus
Directive (the "Qualified Investors")). For these purposes, the expression
"Prospectus Directive" means Directive 2003/71/EC (and amendments thereto,
including the 2010 PD Amending Directive), and includes any relevant
implementing measure in the relevant member state and the expression "2010
PD Amending Directive" means Directive 2010/73/EU.
This announcement contains forward-looking statements that are subject to
certain risks and uncertainties. The future financial results can
significantly differ from the currently anticipated results as a result of
various risks and uncertainties, including changes in the business,
financial and competitive landscape, uncertainties related to legal disputes
or investigations and the availability of funds. SHOP APOTHEKE EUROPE
assumes no obligation to update the forward-looking statements included in
this announcement.
---------------------------------------------------------------------------
13.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
704237 13.07.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC